The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 30, 2013
Filed:
Oct. 15, 2009
Dae Yoon Chi, Seoul, KR;
Byoung SE Lee, Incheon, KR;
Youjung Jung, Gyeonggi-do, KR;
Uthaiwan Sirion, Chainat, TH;
Yoo Jin Lim, Gyeonggi-do, KR;
Yu Jin Bae, Incheon, KR;
Heejun Kim, Seoul, KR;
SO Young Chu, Incheon, KR;
Dae Hyuk Moon, Seoul, KR;
Jin-sook Ryu, Seoul, KR;
Jae Seung Kim, Seoul, KR;
Seung Jun OH, Seoul, KR;
Dae Yoon Chi, Seoul, KR;
Byoung Se Lee, Incheon, KR;
Youjung Jung, Gyeonggi-do, KR;
Uthaiwan Sirion, Chainat, TH;
Yoo Jin Lim, Gyeonggi-do, KR;
Yu Jin Bae, Incheon, KR;
Heejun Kim, Seoul, KR;
So Young Chu, Incheon, KR;
Dae Hyuk Moon, Seoul, KR;
Jin-Sook Ryu, Seoul, KR;
Jae Seung Kim, Seoul, KR;
Seung Jun Oh, Seoul, KR;
Abstract
2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as an active ingredient. Since the 2-arylbenzothiophene derivatives of Formula 1 have a relatively high binding affinity for β-amyloid, they can be used as diagnostic reagents for diagnosing Alzheimer's disease at an early stage by non-invasive techniques when they are labeled with radioisotopes: wherein R-R, V, W, X, Y and Z are as defined in the Detailed Descript of the specification. Further, when the pharmaceutical composition containing the 2-arylbenzothiophene derivative binds with a low-molecular weight β-amyloid peptide binding compound, generation of malignant high-molecular weight β-amyloid deposits is minimized. Accordingly, the pharmaceutical composition can be used as a therapeutic agent of degenerative brain disease such as Alzheimer's disease.